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Abstract 
 
Reported insulin-stimulated glucose removal saturation levels vary widely between 
individuals and trade off with insulin sensitivity in model-based control methods. A 
non-linear model and adaptive insulin infusion protocol enabled high-precision blood 
glucose control in critically ill patients using a constant insulin-stimulated glucose 
removal saturation parameter. Analysis of clinical trial results with and without 
saturation modelling indicates the significant impact of this saturation parameter on 
controller efficacy. Without accounting for saturation, the time-average prediction 
error during a five-hour trial was up to 17.6%. The average prediction error between 
the four patients examined in this study was reduced to 5.8% by approximating the 
saturation parameter. Hence, saturation is an important dynamic that requires good 
methods of estimation or identification to enable tight glycemic control. 
 
Keywords: adaptive control, system modelling, blood glucose, saturation, intensive 
care, drug infusion control 
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1. Introduction  
 
The need to control hyperglycaemia in critical care has been identified by a large 
number of studies (Van den Berghe et al., 2003, Van den Berghe et al., 2001, 
Krinsley, 2003, Krinsley, 2004, Coursin and Murray, 2003). Critically ill patients 
often experience stress-induced hyperglycaemia and severe insulin resistance without 
history of diabetes (e.g. (Capes et al., 2000, Christensen, 2001, Coursin and Murray, 
2003, Finney et al., 2003, Krinsley, 2003, McCowen et al., 2001, Van den Berghe et 
al., 2001, Van den Berghe et al., 2003)). Hyperglycaemia is not only a marker for 
severity of illness, it also worsens outcomes (Van den Berghe et al., 2001, Capes et 
al., 2000, Bistrian, 2001). Tight glucose control has been shown to reduce Intensive 
Care Unit (ICU) patient mortality by 45% if glucose is kept less than 6.1 mmol/L for 
a cardiac care population (Van den Berghe et al., 2003, Van den Berghe et al., 2001). 
Krinsley (Krinsley, 2004) showed a 6% total reduction in mortality over a broader 
critical care population with a higher glucose limit of 7.75 mmol/L. 
 
The ultimate goal of this research is to develop a consistent, robust controller for safe, 
predictable regulation of blood glucose levels in critical care patients. Because 
emerging glucose sensors are still in their infancy, initial implementations of 
automated glycemic control will likely be in a clinical environment. A control 
algorithm capable of tight regulation for a glucose intolerant ICU patient would 
therefore reduce mortality, as well as the burden on medical resources and time, 
relative to current approaches used in most critical care units (Van den Berghe et al., 
2003, Van den Berghe et al., 2001, Krinsley, 2003). 
 
Previous insulin infusion control experiments include Chee et al. (Chee et al., 2002), 
Chase et al  (Chase et al., 2003). and Doran et al. (Doran et al., 2004). Chee et al. 
performed closed-loop glycemic control in critically ill patients using a sliding scale 
algorithm. Chase et al. and Doran et al. used heavy derivative feed-back control to 
regulate blood glucose in the ICU. All three studies showed evidence of insulin effect 
saturation, limiting control effectiveness and patient safety. Therefore, understanding 
saturation is critical in developing a safe, robust and effective control algorithm for 
managing blood glucose levels. 
 
The level at which insulin-stimulated glucose removal saturates varies widely 
between individuals (Natali et al., 2000, Prigeon et al., 1996, Rizza et al., 1981), and 
can impact the insulin sensitivity level identified using mathematical models. More 
specifically, model-based insulin sensitivity appears to decline when saturation 
occurs. When the saturation level is incorrect or, in most cases, not modelled, the 
predictive ability of the controller is significantly compromised. The result is large 
response prediction errors, and hence poor insulin administration. This study 
evaluates the impact of insulin-stimulated glucose removal saturation on dynamic 
modelling and control effectiveness. 
 
2. Glucose-Insulin System Model 
 
The model used in this study is a patient-specific glucose regulatory system model 
extended from the model used by Chase et al. (Chase et al., 2003) and Doran et al. 
(Doran et al., 2004). Insulin utilisation over time and its accumulation dynamics, 
together with its effect saturation, are added to capture the long term effect of 
exogenous insulin and insulin pooling phenomena that were evident in clinical 
glucose control trials [12,13], as well as other literature (e.g. (Thorsteinsson, 1990, 
Prigeon et al., 1996)). 
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where G and I denote the glucose above an equilibrium level, GE, and the plasma 
insulin level respectively. The effect of previously infused insulin utilized over time is 
represented by Q, with k accounting for the effective life of insulin in the system. 
Endogenous glucose removal and insulin sensitivity are pG and SI respectively, V is 
the insulin distribution volume, and n is the first order decay rate for insulin from 
plasma. External nutrition and insulin input are P(t) and uex(t) respectively. Michaelis-
Menten functions are used to define saturation, with αI for saturation of plasma insulin 
disappearance, and αG for saturation of insulin-stimulated glucose removal. 
 
Most models typically use multiple compartments to capture insulin utilisation over 
time (e.g. (Hovorka et al., 2002)). The use of long and short acting insulin 
compartments in Wilinska et al. (Wilinska et al., 2003) provides a similar spreading of 
insulin-glucose utilisation over time. In this model, it is represented by the 
convolution integral in Equation (2). Reported half-life values for IV insulin 
administration range from 25 to 130 minutes (e.g. (Mari and Valerio, 1997, Natali et 
al., 2000, Turnheim and Waldhausl, 1988)). When k approaches infinity, the term 
( ) ( ) ττ τ deIk t tk∫ −−
0
 approaches the instantaneous blood insulin concentration, as in the 
minimal model of Bergman et al. (Bergman et al., 1985). For the clinical trials 
performed in this study, k=0.0099 min-1, for an effective insulin half-life of 70 min. 
 
Prigeon et al. (Prigeon et al., 1996) demonstrated that as peak plasma insulin 
concentration increases in vivo insulin sensitivity, as derived from the minimal model 
drops, providing evidence for insulin saturation in the underestimation of SI using the 
minimal model of Bergmen et al. (Bergman et al., 1985). Prigeon et al. proposed two 
saturable sites; one for insulin transport from plasma to interstitial sites, the other for 
insulin action. Many other studies have supported one or both of these two saturation 
mechanisms (e.g. (Natali et al., 2000, Thorsteinsson, 1990)). Both saturation 
mechanisms are included in this model using Michaelis-Menten functions, which are 
schematically illustrated in Figure 1, in Equations (1) and (3). 
 
The disappearance rate of insulin from plasma is directly proportional to the plasma 
insulin concentration at low plasma insulin level, but becomes independent of the 
plasma insulin level when it exceeds a certain threshold. Thorsteinsson 
(Thorsteinsson, 1990) suggested that insulin removal rate from plasma obeys 
saturation kinetics that can be expressed as a Michaelis-Menten function. In Chase et 
al. (Chase et al., 2003) and Doran et al. (Doran et al., 2004), clinical results also 
suggested the presence of insulin pooling in plasma, where the effect of insulin on 
glucose removal appeared significantly belated. To account for insulin pooling in 
plasma, the parameter αI in Equation (3) bounds the plasma insulin disappearance 
rate. First order insulin disappearance rate from plasma at low insulin concentration, 
n, is set to 0.16 min-1, a value that is fairly consistent across many studies (e.g. 
(Thorsteinsson, 1990)). The value of αI is set to 0.0017 L/mU, which is also consistent 
across many studies (e.g. (Kuehn and Blundell, 1980, Thorsteinsson, 1990)). The 
effect of αI  trades off with insulin clearance n and is very insensitive to a variation in 
the physiological range, due to the small magnitude of the parameter. In addition, the 
impact two compartments from the pharmaco-dynamic Equation (1) is reduced by the 
intervening pharmaco-kinetics of Equation (2). 
 
Saturation in insulin-stimulated glucose removal has been evidenced in several 
clinical investigations. Prigeon et al. (Prigeon et al., 1996) reported that insulin 
sensitivity decreases as peak plasma insulin concentration increases. Caumo et al. 
(Caumo et al., 1999) also reported decreased insulin sensitivity with increased plasma 
insulin level, and that insulin sensitivity becomes independent of plasma insulin level 
as insulin level increases beyond ~40 mU/L. The parameter, αG, in Equation (1) 
defines the saturation of insulin-stimulated glucose removal, where the inverse of αG 
represents the level of insulin integral, or delayed insulin, at which the insulin-
stimulated glucose removal rate reaches half maximum. The plasma insulin 
concentration at which half-maximal glucose utilization occurs as reported by Rizza 
et al. (Rizza et al., 1981) is 55±7 mU/L in 15 healthy adults, and by Prigeon et al. 
(Prigeon et al., 1996) is 65.1 (39.5~71.6) mU/L in 7 obese subjects. The control 
protocol presented currently uses αG=1/65 L/mU as a conservative choice to ensure 
that saturation is more likely to be underestimated. Different levels of αG are tested in 
post-trial simulations to examine the impact of insulin-stimulated glucose removal 
saturation on model prediction using existing trial data. 
 
The model in Equations (1)-(3) does not include endogenous insulin production 
because it can be highly variable and difficult to obtain quickly in critical care, even 
though it is fairly consistent across the healthy population (e.g. (Bergman et al., 1985, 
Hovorka et al., 2002)). Therefore, the effect of endogenous insulin is combined with 
the effect of glucose to enhance glucose removal and inhibit endogenous glucose 
production for the short trials performed in this study. The result is a time-varying 
parameter, pG, that represents the body’s ability to regulate blood glucose without 
exogenous insulin, or more simply, metabolic glucose resistance. 
 
Methods for determining insulin sensitivity have been extensively studied, and it is 
highly dependent on experimental protocol and the dynamic model adopted (e.g. 
(Bettini et al., 1995, Caumo et al., 1999, Beard et al., 1986, DeFronzo et al., 1979)). 
Hyperinsulinemic euglycemic clamp tests with different levels of plasma insulin 
concentration also give very different insulin sensitivity levels including intra-
individual variation (Beard et al., 1986). In Equations (1) to (3), the added saturation 
mechanism on insulin effect in Equation (1) creates a unique index of insulin 
sensitivity, SI, compared to other model-based measures and allows SI to more closely 
approximate the true tissue sensitivity to insulin. 
 
3. Fitting Method and Adaptive Control Algorithm 
The proposed system is controllable, since the three equations are each single-input 
single-output systems, linked together in series. An increase in infused insulin always 
leads to a reduction of blood glucose levels. 
 
To achieve effective targeted glucose reduction, accurate patient specific parameters, 
pG and SI in Equation (1), are crucial. These parameters have been shown to vary over 
time in normal individuals (DeFronzo et al., 1979, Wilinska et al., 2003), and can vary 
significantly in the critically ill. By frequent identification of pG and SI, the controller 
aims to obtain accurate parameter values and capture any variation in the patient’s 
metabolic state due to external perturbations, drug therapy, or changing condition. 
 
Hence, the adaptive controller uses prior data every hour to refit pG and SI. The 
interval of one hour was chosen to better capture variability in patient behaviour due 
to drug therapies or other physiological changes common in critical care patients. The 
insulin bolus size required to reach the target is then found by a bisection method. If 
saturation effects prohibit reaching the target, the target is automatically reset to a 
higher, achievable value. 
 
3.1 Patient Specific Parameter Identification 
Using values from the literature for αG, αI, n, k and V, the only unknowns are pG and 
SI. This study utilizes an integration-based method developed by Hann and Hickman 
(Hann and Hickman, 2002) to identify pG and SI. Both parameters are defined as first 
order piecewise linear to reduce computational intensity while capturing slow 
variations. The method results in a simple convex least squares problem that demands 
little computational time, in contrast to the commonly used non-linear recursive least 
squares routine that is non-convex and starting point dependent (Hovorka and Vicini, 
2001), while still keeping the error small (Lin et al., 2004). In addition, this approach 
is insensitive to measurement noise, a problem with gradient-based methods (Chase et 
al., 2003, Doran et al., 2004), as it effectively low-pass filters the data in the 
numerical integration summations. Constraints are placed on both parameters to 
ensure they are within physiologically valid ranges (e.g (Bettini et al., 1995, Caumo et 
al., 1999, DeFronzo et al., 1979, Hovorka et al., 2002, Mari and Valerio, 1997, Natali 
et al., 2000, Prigeon et al., 1996, Vicini et al., 1997)). 
 
3.2 Influence of saturation and αG on control protocol 
Insulin sensitivity, SI, can trade off with effective insulin saturation limit, αG, in the 
model. In these trials αG is held constant. Adapting the saturation level in real-time is 
difficult because its detection is available only when significant saturation occurs, 
followed by large target error and sudden drop in modelled SI. For patient safety, αG is 
currently set to 1/65 L/mU, corresponding to the highest reported saturation level 
(Prigeon et al., 1996). If the modelled saturation level is too low, the risk of 
administering excess insulin increases, due to seeing the patient as near the saturation 
limit. If a patient does have a low saturation limit, the patient will be seen as more 
insulin resistant, but will not be at risk of hypoglycaemia due to administering excess 
insulin. 
 
4. Clinical Trial Methodology 
 
The clinical control trials consist of an insulin challenge hour followed by four hours 
of tight glycaemic control. Each blood glucose target to be achieved one hour 
onwards is set at the end of that hour, targeting a 10 to 20% hourly reduction. The 
minimum target level is 4.5 mmol/L. Selected patients had to be stable and 
representative of typical ICU conditions, with random blood glucose greater than 8 
mmol/L. Exclusion criteria include: absence of naso-gastric tube or arterial catheter; 
patient being moribund; patients receiving neuromuscular blockade; and body mass 
index above 35 kg/m2. Ethical consent was obtained from the Canterbury Ethics 
Committee. 
 
The trial begins at 0700 hours, at which time any insulin infusion is held constant with 
the standard constant naso-gastric feed maintained throughout the trial. Blood glucose 
is monitored hourly until 1000 hours to determine the patients’ equilibrium blood 
glucose level, GE. At 1000 hours, patients are injected with a 1500 mU ActrapidTM 
insulin bolus via an intravenous cannula using a Graseby 3500 syringe pump. Plasma 
glucose is measured at 15-minute intervals until 1100 hours. The time interval was 
chosen at 15 minutes to provide more frequent data to more accurately determine the 
initial values for pG and SI. Paired blood samples are taken and analyzed using a 
bedside GlucocardTM Test Strip II glucose testing kit, which has 7% error (Arkray Inc. 
2001). 
 
Blood glucose is monitored every 30 minutes after the first hour, and patient specific 
parameters, pG and SI, are refit every hour using data obtained the previous hour. Due 
to the manual measurements of blood glucose by medical staff, a 30 minute interval is 
a compromise between sufficient measurements and work effort. Following each refit, 
the controller determines the insulin bolus required to achieve the targeted glycaemic 
reduction. Hence, the overall approach is a bolus driven, adaptive control method. The 
overall clinical trial procedure is outlined in Figure 2. 
 
5. Post-Trial Simulation 
 
Post-trial simulations were performed using Equations (1)-(3). The insulin infusion 
profile from the clinical trial is run through the model using the same fitting method 
and the control algorithm described. The value for αI was kept constant and αG was 
varied. Three levels of αG were tested, with αG=0 L/mU representing no saturation, 
αG=1/65 L/mU for light saturation, and αG=1/25 L/mU for heavy saturation. The non-
zero values are the lowest and highest values reported from a range of studies (Caumo 
et al., 1999, Natali et al., 2000, Prigeon et al., 1996, Rizza et al., 1981). Predictions for 
the glucose levels after each injection were made and compared to the actual 
measured data to assess the impact of saturation on prediction error, and thus control 
effectiveness. 
 
6. Results and Discussion 
 
Four sets of adaptive glucose control clinical trial data and post-trial simulations are 
presented. 
 
6.1 Trial A 
Patient A was a 71 year old male with a subarachnoid haemorrhage and secondary 
aspiration pneumonia admitted to the ICU three days before the clinical trial. The trial 
began with a blood glucose level of 13.9 mmol/L. The trial was performed using a 
model without saturation (αG=0). The blood glucose levels measured during the trial 
and the impact of varying αG on effective delayed insulin and insulin sensitivity can 
be seen in Figure 3. The impact of varying αG on the controller’s prediction 
performance is presented in Figure 4. 
 
In the trial, the fit to the last hour of measured blood glucose was poor, as seen in 
Figure 3. Insulin-simulated glucose removal saturation was considered to be the cause 
as insulin sensitivity with αG=0 (solid line) dropped significantly at 180 min in Figure 
3. No physiologically valid pG and SI could be found for the fit to go through the last 
hour of data when saturation was not modelled. When αG was increased from 0 to 
1/25 L/mU, or the glucose removal saturation limit lowered, the prediction errors 
diminished significantly. Minimum prediction errors were achieved with αG=1/25 
L/mU, as seen in Figure 4. 
 
The level of αG determines the shape of the delayed insulin curve. When αG>0, the 
area between the delayed insulin curve and the equivalent αG=0 L/m/U curve is the 
ineffective excess insulin. As shown in Figures 3 and 4, prediction errors with 
different αG values start to diverge when the excess (ineffective) insulin is large. This 
result shows how detection of a mis-modelled saturation level only occurs when 
significant saturation occurs, such that the fitted SI in an adaptive scheme becomes 
unable to compensate for the incorrect αG. The result is a sudden significant growth in 
prediction error. This conditional detection of αG makes real-time adaptation of the 
parameter difficult and restricts controller performance. 
 
Prediction errors for the final hour of the trial increased for all three different values 
of αG. The patient was given Metoprolol, a β-blocker that enhances the effect of 
insulin, at approximately 60 minutes with an effective life of 2 to 3 hours. The 
interaction from this drug therapy effectively raised SI from 120 min onwards, as best 
shown by the dotted line in Figure 3. In the last hour of the trial, the effect of 
Metoprolol faded, resulting in significant reduction in SI and larger tracking errors. If 
the trial continued for a few more hours, the tracking error was expected to reduce as 
the controller adapted to match the patient dynamics. 
 
 
 
6.2 Trial B 
Patient B was a 62 year old male initially admitted to the hospital with pneumonia and 
had been in the ICU for four days before the clinical trial. The trial began with a blood 
glucose level of 8.5 mmol/L. The controlled trial was performed without modelling 
saturation (αG=0). The results are shown in Figures 5 and 6. 
 
Patient B was very insulin resistant. Insulin effect saturation was evident in the last 
two hours of the trial, as can be seen from the reluctant reduction in blood glucose 
with 6 units of insulin given per hour. Minimum prediction errors, together with the 
least variation in SI, were achieved with αG=1/25 L/mU. 
 
6.3 Trial C 
Patient C was a 76 year old male admitted into the ICU 33 days before the trial as a 
result of respiratory failure. The controlled trial used αG=1/25 L/mU because it gave 
the best results for Patients A and B. The results are shown in Figures 7 and 8. 
 
In contrast to Patients A and B, this patient had a much higher insulin-stimulated 
glucose removal saturation limit. Post-trial simulation gave the best tracking accuracy 
and smoothest variations in SI when αG=0 L/mU. Although αG is not zero 
physiologically, the result indicates that the patient’s αG value is very low. At 240 
min, the controller demanded a larger bolus than the two previous injections (4.45 vs. 
1.95 and 2.45 U) to try achieve the same percentage reduction because with αG=1/25 
L/mU, the model saw the patient as being at the saturation limit, thus requiring much 
more insulin to achieve the desired level. Although the patient did not suffer a 
hypoglycaemic episode, the need to raise the saturation limit for patient safety was 
clear. Using αG=1/65 L/mU provides physiologically valid dynamics and keeps the 
prediction errors below the measurement error most of the time. 
 
6.4 Trial D 
Patient D was a 62-year-old male Type 2 diabetic admitted to the ICU six days before 
the trial with acute abdominal aortic aneurysm. The level of αG was set to 1/65 L/mU 
in the trial as a conservative choice. Results are shown in Figures 9 and 10. 
 
Post-trial simulations showed that the smoothest variations in SI were achieved when 
αG=1/65 L/mU, as in the trial. The minor discontinuity between each fit of SI indicates 
that the parameters used in the trial were similar to the actual patient values. The first 
two target glucose errors for αG=1/65 L/mU are larger because of the rapid decline in 
SI from 0 to 120 min, which is due to the onset of the trial or the controller adapting 
from initial values. The last two predictions had minimal error, showing that the 
controller had ‘dialled in’ and adapted to match the patient’s dynamics. 
 
7. Conclusions 
 
The clinical control trials conducted during this study demonstrate the potential of the 
control algorithm designed in step-wise set-point regulation of hyperglycaemia and 
real-time tracking of patient dynamics. The model and algorithm developed are 
capable of capturing a patient’s glucose-insulin system dynamics, despite inter-patient 
variability and time varying physiological condition. An integration-based method is 
used for identifying patient specific time-varying parameters in real-time, resulting in 
a convex, computationally simple, linear, least squares solution. 
 
The model includes non-linear saturation of plasma insulin disappearance rate and its 
saturable utilisation to reduce blood glucose levels using Michaelis-Menten functions. 
If the modelled saturation level is too low, the risk of administering excess insulin, 
due to seeing the patient as being at the saturation limit, increases. If a patient does 
have a low saturation limit, the patient will be seen as more insulin resistant, but will 
not be at risk of hypoglycaemia. Post-trial simulations showed that αG can vary 
widely between patients, a fact that is also evident in many other studies on insulin 
effect saturation. 
 
A conservative level of αG=1/65 L/mU is chosen for ongoing control trials to ensure 
patient safety and greater physiological accuracy. The predictive ability of the 
controller can be significantly improved with better estimation of the saturation level. 
Detection of a mis-modelled saturation level only occurs when significant saturation 
occurs, such that the fitted SI in an adaptive scheme becomes unable to compensate 
for the incorrect αG. Hence, the controller’s ability to identify the saturation limit in 
clinical real-time is restricted. Trials spanning longer periods of time are proposed to 
enable αG be adapted, and hence better demonstrate the controller’s predictive and 
adaptive capability. 
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 Figure 1. Michaelis-Menten saturation mechanism 
 
 
 
 
 
Figure 2. Trial methodology 
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 Figure 3. Impact of varying αG for Patient A 
 
Figure 4. Post-trial simulation controller prediction error for Patient A (7% standard 
measurement error) 
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 Figure 5. Impact of varying αG for Patient B 
 
Figure 6. Post-trial simulation controller prediction error for Patient B (7% standard 
measurement error) 
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 Figure 7. Impact of varying αG for Patient C 
 
Figure 8. Post-trial simulation controller prediction error for Patient C (7% standard 
measurement error) 
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 Figure 9. Impact of varying αG for Patient D 
 
Figure 10. Post-trial simulation controller prediction error for Patient D (7% standard 
measurement error) 
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